Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ganaxolone adjunctive therapy for adults with drug-resistant partial-onset seizures
2014-004363-21Phase 3Terminated
- Sponsor
- Marinus Pharmaceuticals
- Start
- Jan 2015
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in epilepsy comparing Ganaxolone adjunctive therapy with Placebo adjunctive therapy (2 arms). Primary endpoint: Primary efficacy endpoint. Started Jan 2015; status: terminated.
02
Drugs
ganaxolone
03
Conditions
epilepsy
Beyond the preview
Go deeper on 2014-004363-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004363-21.